Home > Boards > US Listed > Computers - Hardware > ovid therapeutics inc (ovid)

I’m here as well.. wondering when we’ll get

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
dannyzee84 Member Profile
Member Level 
Followed By 35
Posts 8,064
Boards Moderated 0
Alias Born 02/12/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2020 1:17:05 PM
Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program GlobeNewswire Inc. - 10/14/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/13/2020 4:47:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/13/2020 4:42:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/13/2020 4:39:50 PM
Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Cong... GlobeNewswire Inc. - 10/12/2020 7:00:10 AM
Opthea to Appoint Dr Jeremy Levin as Chairman of the Board GlobeNewswire Inc. - 10/5/2020 5:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/30/2020 8:06:07 AM
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in ... GlobeNewswire Inc. - 9/30/2020 8:00:10 AM
Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/11/2020 8:00:10 AM
ドラベ症候群やレノックス・ガストー症候群の小児を対象とした第2相ELEKTRA試験でソチクレス... Business Wire - 8/27/2020 4:30:00 AM
L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréq... Business Wire - 8/26/2020 6:23:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/26/2020 4:11:39 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/26/2020 4:08:09 PM
Phase-2-Studie ELEKTRA zu Soticlestat (TAK-935/OV935) erreicht primären Endpunkt: Reduktion der Anfallshäufigkeit bei Kinde... Business Wire - 8/25/2020 10:41:00 PM
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock GlobeNewswire Inc. - 8/25/2020 7:50:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/25/2020 7:01:41 AM
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Drave... GlobeNewswire Inc. - 8/25/2020 7:00:10 AM
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Drave... Business Wire - 8/25/2020 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 8:24:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 8:06:53 AM
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 8/10/2020 8:00:10 AM
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020 GlobeNewswire Inc. - 8/5/2020 9:00:10 AM
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of ... GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 ... PR Newswire (US) - 7/13/2020 9:00:00 AM
dannyzee84 Member Level  Thursday, 08/20/20 10:11:57 AM
Re: Munchy post# 11
Post # of 18 
I’m here as well.. wondering when we’ll get that stage 3 news.. also, I see a 100k share wall at 8.40?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences